Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Lymphoma

Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial

Leukemia volume 20, pages 1840–1847 (2006)Cite this article

Abstract

This study provides an updated report of the consecutive multicenter Gruppo Italiano Trapianto Midollo Osseo trial employing an intensified, purging-free, total body irradiation-free, high-dose sequential chemotherapy schedule with peripheral blood stem cell autograft (i-HDS) in advanced-stage follicular lymphoma (FL). Special interest has been devoted to late toxicities and outcome in terms of molecular status. Ninety-two untreated FL patients aged ⩽60 were enrolled by 20 Italian centers and evaluated on an intention-to-treat basis. Main findings are as follows: (1) 5.5-years overall survival projection of 80% (median follow-up: 68 months), with no differences related to age-adjusted IPI score; (2) 46 (50%) of 92 patients presently in continuous complete remission; (3) projected long-term progression-free survival exceeding 80% for patients collecting PCR-negative stem cell harvests or achieving molecular remission within the first 2 years from the end of therapy; (4) actuarial 5-years risk of developing secondary myelodysplasia and acute myeloid leukemia of 3.7%, with most of these events occurring in patients re-treated for recurrent lymphoma. These results demonstrate that i-HDS is feasible, effective and safe even in terms of long-term outcome. As the HDS schedule can be easily supplemented with Rituximab, it is one of the best options for random comparison with Rituximab-supplemented conventional chemotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Morton LM, Wang S, Devesa S, Hartge P, Weisenburger DD, Linet MS . Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265–276.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265.

    Article  PubMed  Google Scholar 

  3. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood 2000; 95: 783–789.

    CAS  PubMed  Google Scholar 

  4. Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C . Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994; 12: 1343–1348.

    Article  CAS  PubMed  Google Scholar 

  5. Rohatiner AZ, Lister TA . The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 2005; 18: 1–10.

    Article  PubMed  Google Scholar 

  6. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269.

    Article  CAS  PubMed  Google Scholar 

  7. Horning SJ . Future directions in radioimmunotherapy for B-cell lymphoma. Semin Oncol 2003; 30: 29–34.

    Article  CAS  PubMed  Google Scholar 

  8. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K et al. I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441–449.

    Article  CAS  PubMed  Google Scholar 

  9. Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A et al. Fludarabinee plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654–2661.

    Article  CAS  PubMed  Google Scholar 

  10. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423.

    Article  CAS  PubMed  Google Scholar 

  11. Hiddemann W, Buske C, Dreyling M, Weigert O, Lenz G, Forstpointner R et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 2005; 23: 6394–6399.

    Article  CAS  PubMed  Google Scholar 

  12. Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch P et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med 1987; 316: 1499–1505.

    Article  CAS  PubMed  Google Scholar 

  13. Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO . High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445–450.

    Article  CAS  PubMed  Google Scholar 

  14. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.

    CAS  PubMed  Google Scholar 

  15. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.

    Article  CAS  PubMed  Google Scholar 

  16. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–3457.

    CAS  PubMed  Google Scholar 

  17. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533.

    Article  CAS  PubMed  Google Scholar 

  18. Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M et al. High rate of clinical and molecular remissions of follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002; 100: 1559–1565.

    Article  CAS  PubMed  Google Scholar 

  19. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780–2786.

    CAS  PubMed  Google Scholar 

  20. Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527–536.

    Article  CAS  PubMed  Google Scholar 

  21. Tarella C, Caracciolo D, Corradini P, Zallio F, Ladetto M, Cuttica A et al. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 2000; 14: 740–747.

    Article  CAS  PubMed  Google Scholar 

  22. Horning SJ, Negrin RS, Hoppe RT, Rosenberg SA, Chao NJ, Long GD et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 2001; 97: 404–409.

    Article  CAS  PubMed  Google Scholar 

  23. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460–1468.

    Article  PubMed  Google Scholar 

  24. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128–3135.

    Article  CAS  PubMed  Google Scholar 

  25. Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: 947–955.

    Article  CAS  PubMed  Google Scholar 

  26. Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: 4926–4933.

    Article  PubMed  Google Scholar 

  27. Deconinck E, Foussard C, Milpied N, Bertrand P, Michenet P, Cornillet-LeFebvre P et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005; 105: 3817–3823.

    Article  CAS  PubMed  Google Scholar 

  28. Lenz G, Dreyling M, Schiegnitz E, Forstpointner R, Wandt H, Freund M et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 2667–2674.

    Article  CAS  PubMed  Google Scholar 

  29. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135.

  30. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.

    CAS  PubMed  Google Scholar 

  31. Federico M, Vitolo U, Zinzani PL, Chisesi T, Clo V, Bellesi G et al. Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. Blood 2000; 95: 783–789.

    CAS  PubMed  Google Scholar 

  32. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265.

    Article  CAS  PubMed  Google Scholar 

  33. Weinstein HJ, Cassady JR, Levey R . Long-term results of the APO protocol (vincristine, doxorubicin (adriamycin), prednisone) for treatment of mediastinal lymphoblastic lymphoma. J Clin Oncol 1983; 1: 537–541.

    Article  CAS  PubMed  Google Scholar 

  34. Tarella C, Zallio F, Caracciolo D, Cuttica A, Corradini P, Gavarotti P et al. High-dose mitoxantrone+melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Leukemia 2001; 15: 256–263.

    Article  CAS  PubMed  Google Scholar 

  35. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244–1253.

    Article  CAS  PubMed  Google Scholar 

  36. Kaplan E, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–463.

    Article  Google Scholar 

  37. Peto R . Asymptotically efficient rank invariant test procedures. J R Stat Soc 1972; 135: 185–206.

    Google Scholar 

  38. Rosthoj S, Andersen PK, Abildstrom SZ . SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed 2004; 74: 69–75.

    Article  PubMed  Google Scholar 

  39. Voena C, Ladetto M, Astolfi M, Provan D, Gribben JG, Boccadoro M et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793–1798.

    Article  CAS  PubMed  Google Scholar 

  40. Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M et al. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp Hematol 2001; 29: 183–193.

    Article  CAS  PubMed  Google Scholar 

  41. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.

    Article  CAS  PubMed  Google Scholar 

  42. Santini G, Nati S, Spriano M, Gallamini A, Pierluigi D, Congiu AM et al. Fludarabinee in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma. Haematologica 2001; 86: 282–286.

    CAS  PubMed  Google Scholar 

  43. Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B et al. The addition of rituximab to a combination of fludarabinee, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071.

    Article  CAS  PubMed  Google Scholar 

  44. Hardingham JE, Kotasek D, Sage RE, Gooley LT, Mi JX, Dobrovic A et al. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 1073–1079.

    Article  CAS  PubMed  Google Scholar 

  45. Moos M, Schulz R, Martin S, Benner A, Haas R . The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma. Leukemia 1998; 12: 1971–1976.

    Article  CAS  PubMed  Google Scholar 

  46. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533.

    Article  CAS  PubMed  Google Scholar 

  47. Corradini P, Astolfi M, Cherasco C, Ladetto M, Voena C, Caracciolo D et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89: 724–731.

    CAS  PubMed  Google Scholar 

  48. Rambaldi A, Lazzari M, Manzoni C, Carlotti E, Arcaini L, Baccarani M et al. Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma. Blood 2002; 99: 856–862.

    Article  CAS  PubMed  Google Scholar 

  49. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516–522.

    Article  CAS  PubMed  Google Scholar 

  50. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabinee, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005; 105: 4573–4575.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Lam CC, Ma ES, Kwong YL . Therapy-related acute myeloid leukemia after single-agent treatment with fludarabinee for chronic lymphocytic leukemia. Am J Hematol 2005; 79: 288–290.

    Article  PubMed  Google Scholar 

  52. Tarella C, Gianni AM . Bone marrow transplantation for lymphoma CR1. Curr Opin Oncol 2005; 17: 99–105.

    Article  PubMed  Google Scholar 

  53. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM . Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 2208–2214.

    Article  CAS  PubMed  Google Scholar 

  54. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL . New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21: 1352–1358.

    Article  PubMed  Google Scholar 

  55. Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96: 864–869.

    CAS  PubMed  Google Scholar 

  56. Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D et al. Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001; 15: 1941–1949.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Investigators from the following Institutions in Italy contributed to the trial: Divisione Universitaria di Ematologia, Cattedra di Ematologia (Torino): M Ladetto, S Vallet, M Boccadoro, C Tarella, I Ricca, M Zanni, F De Marco, C Tarella; Divisione Universitaria di Ematologia, Policlinico Borgo Roma (Verona): F Benedetti, M Sorio, G Pizzolo; Divisione Ospedaliera di Ematologia, AO S Giovanni Battista (Torino): U Vitolo, C Boccomini, A Chiappella, E Gallo; Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza (Roma): M Martelli, MT Petrucci, A Pulsoni, F Mandelli; Dipartimento di Ematologia, AO Bianchi-Melacrino-Morelli (Reggio Calabria): V Callea, C Stelitano, G Messina, M Brugiatelli, F Nobile; Divisione di Ematologia, AO S Maurizio (Bolzano/Bozen): P Coser, S Cortelazzo, N Pescosta; Divisione Universitaria di Ematologia, AO S Eugenio, Università Tor Vergata (Roma): A Perrotti, S Amadori; Divisione di Ematologia, AO V Cervello (Palermo): C Patti, S Mirto, R Scimè, I Majolino; Divisione Universitaria di Ematologia, AO Spirito Santo (Pescara): G Fioritoni, F Angrilli; Divisione di Ematologia-CTMO, Ospedale Maggiore (Cremona): S Morandi, C Bergonzi; Divisione di Oncoematologia e TMO, Ospedale La Maddalena (Palermo): M Musso; Bone Marrow Transplantation Unit, Istituto Scientifico HS Raffaele (Milano): P Corradini, A Pescarollo, M Bregni, Division of Medical Oncology, Istituto Nazionale Tumori, Milano, Italy: P Corradini, F Zallio; Divisione di Ematologia, AO S Bortolo (Vicenza): R Zambello, F Rodeghiero; Divisione di Ematologia, Ospedali Riuniti SS. Giovanni e Paolo, (Venezia): T Chisesi; Divisione di Ematologia, AO Casa Sollievo della Sofferenza (S Giovanni Rotondo): N Di Renzo; Divisione di Ematologia, AO S Chiara (Trento): P Vivaldi; Divisione di Medicina Generale, Ospedale S Giovanni Vecchio antica sede (Torino): A De Crescenzo; Divisione di Ematologia, AO S Croce (Cuneo): A Gallamini, C Castellino; Divisione di Ematologia, AO SS Antonio e Biagio (Alessandria): F Salvi, A Levis; Dipartimento di Ematologia, AO S Martino (Genova): G Santini. This work was supported by Compagnia di San Paolo, Torino, Italy and by Regione Piemonte. IR is a recipient of a fellowship from AIRC.

Author information

Authors and Affiliations

  1. Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy

    M Ladetto, S Vallet, M Boccadoro, F De Marco, M Zanni & C Tarella

  2. Divisione Universitaria di Ematologia, Policlinico Borgo Roma, Verona, Italy

    F Benedetti & M Sorio

  3. Divisione Ospedaliera di Ematologia, Azienda Ospedaliera S Giovanni Battista, Torino, Italy

    U Vitolo & C Boccomini

  4. Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma, Italy

    M Martelli & A Pulsoni

  5. Divisione di Ematologia, Ospedali Riuniti, Reggio Calabria, Italy

    V Callea & C Stelitano

  6. Divisione di Ematologia, Azienda Ospedaliera V Cervello, Palermo, Italy

    C Patti & R Scimè

  7. Divisione di Ematologia, Azienda Ospedaliera S Maurizio, Bolzano/Bozen, Italy

    P Coser

  8. Divisione Universitaria di Ematologia, Azienda Ospedaliera S Eugenio, Università Tor Vergata, Roma, Italy

    A Perrotti

  9. SCDU Epidemiologia dei Tumori, Azienda Ospedaliera S Giovanni Battista, Torino, Italy

    R Rosato

  10. Bone Marrow Trasplantation Unit, Istituto Scientifico HS Raffaele, Milano, Italy

    P Corradini

  11. Division of Medical Oncology, Istituto Nazionale Tumori, Milano, Italy

    P Corradini

Authors
  1. M Ladetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Vallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Benedetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. U Vitolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Martelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V Callea
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Patti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P Coser
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Perrotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Sorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. C Boccomini
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Pulsoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C Stelitano
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R Scimè
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M Boccadoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. R Rosato
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. F De Marco
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. M Zanni
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. P Corradini
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. C Tarella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Ladetto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ladetto, M., Vallet, S., Benedetti, F. et al. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia 20, 1840–1847 (2006). https://doi.org/10.1038/sj.leu.2404346

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404346

Keywords

This article is cited by

Search

Advanced search

Quick links